Search Result

Results for "

cAMP accumulation

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenosine Receptor (6) Adrenergic Receptor (9) Akt (2) Cannabinoid Receptor (2) CFTR (1) CGRP Receptor (2) CRFR (1) Dopamine Receptor (1) ERK (2) Free Fatty Acid Receptor (1) G protein-coupled Bile Acid Receptor 1 (1) GLP Receptor (3) GPR52 (1) GPR84 (1) Isotope-Labeled Compounds (3) mAChR (1) mGluR (3) Mineralocorticoid Receptor (1) Monoamine Oxidase (1) p38 MAPK (2) PACAP Receptor (1) Phosphodiesterase (PDE) (1) PKA (2) PPAR (2)
By Research Areas:	Cancer (5) Cardiovascular Disease (7) Endocrinology (9) Inflammation/Immunology (8) Metabolic Disease (9) Neurological Disease (12)

By Targets:

Adenosine Receptor (6)

Adrenergic Receptor (9)

Akt (2)

Cannabinoid Receptor (2)

CFTR (1)

CGRP Receptor (2)

CRFR (1)

Dopamine Receptor (1)

ERK (2)

Free Fatty Acid Receptor (1)

G protein-coupled Bile Acid Receptor 1 (1)

GLP Receptor (3)

GPR52 (1)

GPR84 (1)

Isotope-Labeled Compounds (3)

mAChR (1)

mGluR (3)

Mineralocorticoid Receptor (1)

Monoamine Oxidase (1)

p38 MAPK (2)

PACAP Receptor (1)

Phosphodiesterase (PDE) (1)

PKA (2)

PPAR (2)

By Research Areas:

Cancer (5)

Cardiovascular Disease (7)

Endocrinology (9)

Inflammation/Immunology (8)

Metabolic Disease (9)

Neurological Disease (12)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-131032

KI-7	Adenosine Receptor	Others
KI-7 is an A2B adenosine receptor positive allosteric modulator. KI-7 potentiates the cAMP accumulation induced by the non-selective A2B adenosine receptor agonist NECA (EC₅₀=445.8 nM). KI-7 also potentiates the cAMP accumulation induced by the selective A2B adenosine receptor agonist BAY 60-6583 as well as by adenosine with EC₅₀s of 2390 nM and 2550 nM, respectively .

HY-147395

GPR52 agonist-1	GPR52	Neurological Disease
GPR52 agonist-1 is a potent, orally active and blood-brain barrier (BBB) penetrant GPR52 agonist with an pEC₅₀ value of 7.53. GPR52 agonist-1 affects cAMP accumulation through direct interaction with GPR52. GPR52 agonist-1 can significantly suppress Methamphetamine-induced hyperactivity in mice. Antipsychotic activity .

HY-16642A

LY2828360	Cannabinoid Receptor	Neurological Disease
LY2828360 is a slowly acting but efficacious G protein-biased cannabinoid (CB₂) agonist, inhibiting cAMP accumulation and activating ERK1/2 signaling.

HY-P4127A

M65 TFA	PACAP Receptor	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
M65 TFA is a deleted peptide of maxadilan (61 a.a.) with deletion of the residues between positions 24 and 42 and is a specific antagonist of PACAP type 1 receptor that inhibits ANP secretion and can be used for relevant researches .

HY-19026

Siguazodan SKF 94836	Phosphodiesterase (PDE)	Cardiovascular Disease
Siguazodan (SKF 94836) is a potent, selective and orally active phosphodiesterase III (PDE-III) inhibitor with an IC₅₀ of 117 nM. Siguazodan increases cAMP accumulation in intact platelets with an EC₅₀ of 18.88 μM. Siguazodan also inhibits phenylephrine-induced 5-HT release with an IC₅₀ value of 4.2 μM .

HY-161817

TGR5 agonist 5	G protein-coupled Bile Acid Receptor 1	Others
TGR5 agonist 5 (compound K91) is a potent agonist of TGR5, with EC₅₀s of 19 μM and 30 μM in CRE-Luciferase assay anf cAMP accumulation assay, respectively .

HY-106303

YT 146	Adenosine Receptor	Cardiovascular Disease
YT 146 is a potent agonist of A2 adenosine receptor (A2 AR) agonist. YT 146 causes a concentreation dependent cAMP accumulation, with the EC₅₀ of 1.5 nM. YT 146 has cardioprotective effects .

HY-149933

AM841	Cannabinoid Receptor	Neurological Disease
AM841 is a high-affinity electrophilic ligand. AM841 interacts covalently with a cysteine in helix six and activates the CB1 cannabinoid receptor. AM841 reduces Forskolin (HY-15371)-stimulated cAMP accumulation. AM841 also slows gastrointestinal motility .

HY-U00341

ST4206	Adenosine Receptor	Neurological Disease
ST4206 is a potent and orally active adenosine A2A receptor antagonist, with K_is of 12 nM and 197 nM for adenosine A2A receptor and adenosine A1 receptor, respectively. ST4206 has the potential for Parkinson׳s disease research .

HY-19436A

Solabegron hydrochloride GW 427353B	Adrenergic Receptor	Metabolic Disease Endocrinology
Solabegron hydrochloride is a selective β₃-adrenergic receptor agonist, stimulating cAMP accumulation in Chinese hamster ovary cells expressing the human β₃-AR, with an EC₅₀ value of 22 nM . Solabegron hydrochloride (GW 427353) is being developed for the treatment of overactive bladder and irritable bowel syndrome .

HY-14302

Salmeterol 5+ Cited Publications GR33343X	Adrenergic Receptor	Inflammation/Immunology Endocrinology
Salmeterol (GR33343X) is a potent and selective human β2 adrenoceptor agonist. Salmeterol shows potent stimulation of cAMP accumulation in CHO cells expressing human β2, β1 and β3 adrenoceptors with pEC₅₀s of 9.6, 6.1, and 5.9, respectively .

HY-163996

DD202-114	GLP Receptor	Metabolic Disease
DD202-114 is a potent and selective GLP1R agonist. DD202-114 promots cAMP accumulation. DD202-114 reduces blood glucose levels and food intake. DD202-114 has the potential for the research of type 2 diabetes (T2DM) and obesity .

HY-P5950

ACTH (6-24) (human) Adrenocorticotropic hormone (6-24)	Mineralocorticoid Receptor	Cardiovascular Disease
ACTH (6-24) (human) (Adrenocorticotropic hormone (6-24)) is an ACTH fragment. ACTH (6-24) (human) is a competitive inhibitor of steroidogenesis induced by ACTH (1-39) and ACTH (5-24) (K_d:13.4 and 3.4 nM). ACTH (6-24) (human) inhibits corticosterone production and cAMP accumulation induced by hPTH 1-34 .

HY-17453

Salmeterol xinafoate 5+ Cited Publications GR 33343X xinafoate	Adrenergic Receptor	Inflammation/Immunology Endocrinology
Salmeterol (GR 33343X) xinafoate is a potent and selective human β2 adrenoceptor agonist. Salmeterol shows potent stimulation of cAMP accumulation in CHO cells expressing human β2, β1 and β3 adrenoceptors with pEC₅₀s of 9.6, 6.1, and 5.9, respectively .

HY-19436

Solabegron 1 Publications Verification GW 427353	Adrenergic Receptor	Metabolic Disease Endocrinology
Solabegron (GW 427353) is a selective β₃-adrenergic receptor agonist, stimulating cAMP accumulation in Chinese hamster ovary cells expressing the human β₃-AR, with an EC₅₀ value of 22 nM . Solabegron (GW 427353) is being developed for the treatment of overactive bladder and irritable bowel syndrome .

HY-124571

ZQ-16	GPR84	Inflammation/Immunology
ZQ-16 is a potent and selective GPR84 agonist with an EC₅₀ value of 0.213 μM. ZQ-16 has no activity on the other free fatty acid receptors (FFARs), including GPR40, GPR41, GPR119 and GPR120 .

HY-135119

Salmeterol-d3	Adrenergic Receptor	Inflammation/Immunology Endocrinology
Salmeterol-d₃ is a deuterium labeled Salmeterol. Salmeterol is a potent and selective human β2 adrenoceptor agonist. Salmeterol shows potent stimulation of cAMP accumulation in CHO cells expressing human β2, β1 and β3 adrenoceptors with pEC50s of 9.6, 6.1, and 5.9, respectively[1].

HY-14302S1

Salmeterol-d5 GR33343X-d₅	Isotope-Labeled Compounds Adrenergic Receptor	Endocrinology
Salmeterol-d5 is a deuterated labeled Salmeterol . Salmeterol (GR33343X) is a potent and selective human β2 adrenoceptor agonist. Salmeterol shows potent stimulation of cAMP accumulation in CHO cells expressing human β2, β1 and β3 adrenoceptors with pEC₅₀s of 9.6, 6.1, and 5.9, respectively .

HY-119333

NNC 11-1607	mAChR	Neurological Disease
NNC 11-1607 is a selective M1/M4 muscarinic acetylcholine receptor (mAChR) agonist. NNC 11-1607 inhibits Forskolin (HY-15371)-stimulated cAMP accumulation in Chinese hamster ovary cells expressing the human M2 or M4 mAChR. NNC 11-1607 is promising for research of central nervous system disorders, such as Alzheimer’s disease and schizophrenia .

HY-17453S

Salmeterol-d3 xinafoate GR 33343X-d₃ xinafoate	Isotope-Labeled Compounds Adrenergic Receptor	Inflammation/Immunology Endocrinology
Salmeterol-d₃ (xinafoate) is the deuterium labeled Salmeterol xinafoate. Salmeterol (GR 33343X) xinafoate is a potent and selective human β2 adrenoceptor agonist. Salmeterol shows potent stimulation of cAMP accumulation in CHO cells expressing human β2, β1 and β3 adrenoceptors with pEC50s of 9.6, 6.1, and 5.9, respectively[1].

HY-103565

AMN082	mGluR	Neurological Disease
AMN082, a selective, orally active, and brain penetrant mGluR7 agonist, directly activates receptor signaling via an allosteric site in the transmembrane domain. AMN082 potently inhibits cAMP accumulation and stimulates GTPγS binding (EC₅₀ values, 64-290 nM) at transfected mammalian cells expressing mGluR7. AMN082 shows selectivity over other mGluR subtypes and selected ionotropic glutamate receptors. Antidepressant effects .

HY-17453S1

Salmeterol-13C6 xinafoate GR 33343X-¹³C₆ xinafoate	Isotope-Labeled Compounds Adrenergic Receptor	Inflammation/Immunology Endocrinology
Salmeterol- ¹³C₆ (xinafoate) is the ¹³C₆ labeled Salmeterol (xinafoate). Salmeterol (GR 33343X) xinafoate is a potent and selective human β2 adrenoceptor agonist. Salmeterol shows potent stimulation of cAMP accumulation in CHO cells expressing human β2, β1 and β3 adrenoceptors with pEC50s of 9.6, 6.1, and 5.9, respectively.

HY-162787

Adenosine receptor antagonist 5	Adenosine Receptor	Cancer
Adenosine receptor antagonist 5 (Compound 39) is a selective antagonist for human adenosine A3 receptor (hA3R) with K_i of 12 nM. Adenosine receptor antagonist 5 inhibits IB-MECA (HY-13591)-induced cAMP accumulation in NCI-H1792 cell, inhibits the proliferation of cancer cell LK-2 and NCI-H1792. Adenosine receptor antagonist 5 exhibits a fast metabolic rate in human liver microsomes .

HY-17453R

Salmeterol (xinafoate) (Standard)	Adrenergic Receptor	Inflammation/Immunology Endocrinology
Salmeterol (xinafoate) (Standard) is the analytical standard of Salmeterol (xinafoate). This product is intended for research and analytical applications. Salmeterol (GR 33343X) xinafoate is a potent and selective human β2 adrenoceptor agonist. Salmeterol shows potent stimulation of cAMP accumulation in CHO cells expressing human β2, β1 and β3 adrenoceptors with pEC50s of 9.6, 6.1, and 5.9, respectively .

HY-100403

Ro 67-7476 Maximum Cited Publications 12 Publications Verification	mGluR	Cancer
Ro 67-7476 is a potent positive allosteric modulator of mGluR₁ and potentiates glutamate-induced calcium release in HEK293 cells expressing rat mGluR1a with an EC₅₀ of 60.1 nM . Ro 67-7476 is a potent P-ERK1/2 agonist?and activates ERK1/2 phosphorylation in the absence of exogenously added glutamate (EC₅₀=163.3 nM) .

HY-P1106

K41498	CRFR	Cardiovascular Disease
K41498 is a potent and highly selective CRF2 receptor antagonist with K_i values of 0.66 nM, 0.62 nM and 425 nM for human CRF_2α, CRF_2β and CRF₁ receptors respectively. K41498 is an analogues of antisauvagine-30 (aSvg-30), inhibits sauvagine-stimulated cAMP accumulation in hCRF_2α- and hCRF_2β-expressing cells. K41498 can be used for hypotension study .

HY-168481

GLP-1R agonist 27	GLP Receptor	Metabolic Disease
GLP-1R agonist 27 (compound 21) is a potent and orally active GLP-1R agonist. GLP-1R agonist 27 promots cyclic adenosine monophosphate (cAMP) accumulation. GLP-1R agonist 27 reduces blood glucose levels and food intake. GLP-1R agonist 27 has the potential for the research of obesity and type 2 diabetes mellitus (T2DM) .

HY-103565A

AMN082 free base	mGluR	Neurological Disease
AMN082 free base, a selective, orally active, and brain penetrant mGluR7 agonist, directly activates receptor signaling via an allosteric site in the transmembrane domain. AMN082 free base potently inhibits cAMP accumulation and stimulates GTPγS binding (EC₅₀ values, 64-290 nM) at transfected mammalian cells expressing mGluR7. AMN082 free base shows selectivity over other mGluR subtypes and selected ionotropic glutamate receptors. Antidepressant effects .

HY-N2118

Bilobetin 2 Publications Verification	PPAR PKA Akt p38 MAPK ERK	Metabolic Disease
Bilobetin, an active component of Ginkgo biloba, can reduce blood lipids and improve the effects of insulin. Bilobetin ameliorated insulin resistance, increased the hepatic uptake and oxidation of lipids, reduced very-low-density lipoprotein triglyceride secretion and blood triglyceride levels, enhanced the expression and activity of enzymes involved in β-oxidation and attenuated the accumulation of triglycerides and their metabolites in tissues. Bilobetin also increased the phosphorylation, nuclear translocation and activity of PPARα accompanied by elevated cAMP level and PKA activity .

HY-114539

L-750667 triHydrochloride	Dopamine Receptor	Neurological Disease
L-750667 triHydrochloride is a selective antagonist for the D4 dopamine receptor, with a K_i value of 0.51 nM. The radiolabeled form of L-750667, [ ¹²⁵I]L-750,667, has a K_d value of 0.16 nM for the D4 receptor. L-750667 triHydrochloride can reverse dopamine-induced inhibition of cAMP accumulation. It can be used to study the distribution and function of D4 dopamine receptors in the central nervous system and has potential applications in the fields of neuroscience and psychiatry .

HY-P1106A

K41498 TFA	CFTR	Cardiovascular Disease
K41498 TFA is a potent and highly selective CRF2 receptor antagonist with K_i values of 0.66 nM, 0.62 nM and 425 nM for human CRF_2α, CRF_2β and CRF₁ receptors respectively. K41498 TFA is an analogues of antisauvagine-30 (aSvg-30), inhibits sauvagine-stimulated cAMP accumulation in hCRF_2α- and hCRF_2β-expressing cells. K41498 TFA can be used for hypotension study .

HY-109139

Taminadenant 1 Publications Verification NIR178; PBF509	Adenosine Receptor	Neurological Disease Cancer
Taminadenant (NIR178; PBF509) is a highly potent and orally active adenosine A_2A receptor (A_2AR) antagonist. Taminadenant can antagonize A2AR agonist-mediated cAMP accumulation and impedance responses with K_B values of 72.8 nM and 8.2 nM, respectively. Taminadenant reverses motor impairments in several rat models of movement disorders, including catalepsy, tremor, and hemiparkinsonism. Taminadenant can also inhibit tumor growth when combined with Spartalizumab (HY-P9972). Taminadenant reactivate the antitumor immune response .

HY-171069

FFA2 agonist-1	Free Fatty Acid Receptor	Metabolic Disease
FFA2 agonist-1 (Compound 4) is the agonist for Free fatty acid receptor 2 (FFA2/GPR43) with an EC₅₀ of 81 nM. FFA2 agonist-1 exhibits activity in β-arrestin-2 recruitment assay and cAMP inhibition assay with EC₅₀ of 1.2 μM and 0.53 μM. FFA2 agonist-1 leads to appetite regulating peptide YY (PYY) mucosal responses, inhibits the fat accumulation, intestinal functions and food intake, and can be used for obesity research .

HY-N2118R

Bilobetin (Standard)	PPAR PKA Akt p38 MAPK ERK	Metabolic Disease
Bilobetin (Standard) is the analytical standard of Bilobetin. This product is intended for research and analytical applications. Bilobetin, an active component of Ginkgo biloba, can reduce blood lipids and improve the effects of insulin. Bilobetin ameliorated insulin resistance, increased the hepatic uptake and oxidation of lipids, reduced very-low-density lipoprotein triglyceride secretion and blood triglyceride levels, enhanced the expression and activity of enzymes involved in β-oxidation and attenuated the accumulation of triglycerides and their metabolites in tissues. Bilobetin also increased the phosphorylation, nuclear translocation and activity of PPARα accompanied by elevated cAMP level and PKA activity .

HY-P0165B

Taspoglutide acetate ITM077 acetate; R1583 acetate; BIM51077 acetate	GLP Receptor	Metabolic Disease
Taspoglutide (R1583) acetate is an agonist of the glucagon-like peptide 1 receptor (GLP-1R) with an K_i value of 1.1 nM. Taspoglutide acetate induces cAMP accumulation in CHO-K1 cells expressing human GLP-1R (EC₅₀ = 0.06 nM). Taspoglutide acetate decreases blood levels of glucose and increases blood levels of insulin in a glucose tolerance test in Zucker diabetic obese rats. Taspoglutide acetate reduces blood levels of gastric inhibitory polypeptide (GIP), plasma levels of triglycerides, and body weight in the same model .

HY-120826

A2AAR/hMAO-B-IN-1	Monoamine Oxidase Adenosine Receptor	Neurological Disease
A2AAR/hMAO-B-IN-1 (compoudn 17) is a non-xanthine dual-target inhibitor targeting the A2A adenosine receptor (A2AAR) (IC₅₀: 34.9 nM) andMAO-B (Ki: 39.5 nM, human). A2AAR/hMAO-B-IN-1 inhibits A2AAR-induced cAMP accumulation and exhibits competitive, reversible inhibition of MAO-B. A2AAR/hMAO-B-IN-1 can be used in the study of neurodegenerative diseases such as Parkinson's disease (PD) .

HY-P1471

Adrenomedullin (AM) (22-52), human 1 Publications Verification 22-52-Adrenomedullin (human)	CGRP Receptor	Cardiovascular Disease
Adrenomedullin (AM) (22-52), human, an NH2 terminal truncated adrenomedullin analogue, is an adrenomedullin receptor antagonist, and also antagonizes the calcitonin generelated peptide (CGRP) receptor in the hindlimb vascular bed of the cat .

HY-P1471A

Adrenomedullin (AM) (22-52), human TFA 22-52-Adrenomedullin (human) (TFA)	CGRP Receptor	Cardiovascular Disease
Adrenomedullin (AM) (22-52), human (22-52-Adrenomedullin human) TFA, an NH₂ terminal truncated adrenomedullin analogue, is an adrenomedullin receptor antagonist. Adrenomedullin (AM) (22-52), human also antagonizes the calcitonin generelated peptide (CGRP) receptor in the hindlimb vascular bed of the cat .

HY-113513

5-HEPE	Others	Cancer
5(S)-HEPE is an active metabolite of eicosapentaenoic acid. It is formed from EPA by 5-lipoxygenase (5-LO). 5(S)-HEPE is an agonist of G protein-coupled receptor 119 (GPR119). It increases cAMP accumulation in CHO-K1 cells expressing human GPR119 when used at a concentration of 10 μM. 5(S)-HEPE increases glucose-induced insulin secretion from MING6 insulinoma pancreatic islets and glucagon-like peptide 1 (GLP-1) secretion from HuTu 80 adenocarcinoma cells when used at a concentration of 10 μM. Serum levels of 5(S)-HEPE are elevated in patients with hyperlipidemia.

Cat. No.	Product Name	Target	Research Area